KISSUNLA Trademark

Trademark Overview


On Monday, February 28, 2022, a trademark application was filed for KISSUNLA with the United States Patent and Trademark Office. The USPTO has given the KISSUNLA trademark a serial number of 97287390. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Tuesday, July 16, 2024. This trademark is owned by Eli Lilly and Company. The KISSUNLA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascula...
kissunla

General Information


Serial Number97287390
Word MarkKISSUNLA
Filing DateMonday, February 28, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateTuesday, July 16, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 13, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, March 3, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Thursday, March 3, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 3, 2022NEW APPLICATION ENTERED
Friday, November 4, 2022ASSIGNED TO EXAMINER
Friday, November 4, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 23, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 7, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, July 20, 2023SOU EXTENSION 1 FILED
Tuesday, December 13, 2022PUBLISHED FOR OPPOSITION
Tuesday, December 13, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, July 20, 2023SOU TEAS EXTENSION RECEIVED
Thursday, July 20, 2023SOU EXTENSION 1 GRANTED
Saturday, July 22, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 16, 2024SOU EXTENSION 2 GRANTED
Tuesday, January 16, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, January 16, 2024SOU EXTENSION 2 FILED
Tuesday, July 16, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, July 16, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 16, 2024SOU EXTENSION 3 FILED
Tuesday, July 16, 2024SOU EXTENSION 3 GRANTED
Thursday, January 18, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED